{"nctId":"NCT01747330","briefTitle":"Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency","startDateStruct":{"date":"2012-06"},"conditions":["Pancreatic Exocrine Insufficiency"],"count":40,"armGroups":[{"label":"Creon micro, minimicrospheres","type":"EXPERIMENTAL","interventionNames":["Drug: Pancreatin"]}],"interventions":[{"name":"Pancreatin","otherNames":["Creon micro"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Children younger than four years with confirmed cystic fibrosis diagnosis and a body weight of at least 2 kilograms\n\nExclusion Criteria:\n\n* Ileus or acute abdomen\n* history of fibrosing colonopathy\n* history of distal ileal obstruction without surgery\n* solid organ transplant or surgery affecting the large bowel, other than appendectomy","healthyVolunteers":false,"sex":"ALL","maximumAge":"4 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Body Weight","description":"change from baseline at day 84","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.61"}]}]}]},{"type":"PRIMARY","title":"Height","description":"change from baseline at day 84","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.026","spread":"0.020"}]}]}]},{"type":"PRIMARY","title":"Stool Frequency","description":"Average daily stool frequency during treatment period: Number of bowel movements per day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.8"}]}]}]},{"type":"PRIMARY","title":"Stool Consistency","description":"Assessment of stool consistency by the caregiver on a daily basis: hard, formed/normal, soft, watery","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":"26.4"}]}]}]},{"type":"PRIMARY","title":"Subject's Acceptance of Treatment","description":"Acceptance to Creon Micro. The caregiver should give his/her opinion based on the following scale: very good, good, moderate, and unsatisfactory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Pulse","description":"Change from Baseline at Day 84","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"9.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Findings During Physical Examination","description":"A physical examination was conducted by the physician. All abnormal findings were recorded as medical histories if present prior to start of study drug or as AEs otherwise. There was no separate documentation of physical examination findings in this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical Relevant Safety Laboratory Values","description":"(hematology: hemoglobin, hematocrit, RBC count, WBC count, platelet count; biochemistry: glucose (fasting), creatinine, alkaline phosphatase, total bilirubin, ALAT (alanine amino transferase), ASAT (aspartate amino transferase), gamma-glutamyl transferase, uric acid, calcium, phosphate, potassium, serum pancreatic lipase; urinalysis (dipstick): glucose, blood, albumin, pH)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":["infections NEC","upper respiratory tract infections","gastrointestinal spastic and hypermotility disorders"]}}}